GLP-1 weight loss drugs

A new study finds that people who stop taking GLP-1 weight-loss and diabetes drugs, such as Ozempic and Wegovy, may face an increased risk of heart attack and stroke. The findings suggest the cardiovascular benefits of these medications depend on continued use, raising questions about how patients should manage long-term treatment.

GLP-1 weight-loss drugs such as Ozempic and Wegovy are being linked to changes in sleep health, with researchers examining how significant weight loss affects sleep apnoea and other sleep disorders. The trend is prompting sleep medicine specialists to rethink diagnosis rates, treatment demand and how therapies like CPAP may be used as more patients take these medications.

Doctors are warning that people taking GLP-1 weight-loss and diabetes drugs such as Ozempic may face heightened health risks during the current heat wave. Concerns center on dehydration, as the medications can suppress thirst and appetite, potentially leaving users vulnerable to heat exhaustion and related complications. Patients are being advised to drink water regularly and take precautions in high temperatures as extreme heat persists across many regions.

A functional medicine expert is cautioning that high doses of GLP-1 weight-loss and diabetes drugs may affect more than appetite, potentially disrupting other bodily processes beyond food cravings. The warning, reported by Fox News, adds to ongoing debate about the safety and long-term effects of medications such as Ozempic and Wegovy as their use continues to expand.

A new study reports that about one in six children taking GLP-1 medications, such as Ozempic and Wegovy, developed nutritional deficiencies while on the drugs. The findings raise concerns that appetite suppression and reduced intake may leave some children short on key nutrients, prompting calls for closer monitoring of children prescribed these increasingly used weight-loss medications.

Health experts say weight loss drugs such as GLP-1 medications could offer benefits beyond slimming, potentially helping treat women's reproductive health issues. The suggestion points to a possible new use for a class of medicines already in high demand, and it is drawing attention to how obesity-related treatments might intersect with conditions like polycystic ovary syndrome and fertility problems.

A new study has connected the use of GLP-1 weight-loss and diabetes medications in children with nutritional deficiencies, according to Scripps News, which published an interactive report on the findings. The drugs, widely prescribed to minors amid rising childhood obesity rates, may leave young users short of key nutrients. The findings add to ongoing debate over the safety and supervision of GLP-1 treatment in pediatric patients.

New Zealand dairy giant Fonterra is moving to serve the nutritional needs of people taking weight-loss medications such as GLP-1 drugs, which reduce appetite and can leave users short of protein and key nutrients. The company is positioning high-protein dairy products to fill that gap, tapping into one of the fastest-growing trends in global food and health.

Public health coverage is drawing together two related topics: the possible mental health effects of GLP-1 weight-loss and diabetes drugs, and the role of exercise for women going through menopause. Listeners are weighing reported mood changes linked to GLP-1 medications against growing evidence that physical activity can ease menopause symptoms such as hot flashes, sleep problems and weight gain.